{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:09:54Z","timestamp":1794492594641,"version":"4.9.1"},"reference-count":31,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2018,3,28]]},"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To describe the clinical features, treatment and visual outcomes of Japanese patients with new-onset acute Vogt-Koyanagi-Harada (VKH) disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical records of 111 patients who presented between 1999 and 2015 to the Ocular Inflammation Service of the Kyorin Eye Center, Tokyo, were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 111 patients (68 women, 43 men), 16 had complete, 90 had incomplete and 5 had probable VKH disease. The median follow-up period was 36 months\u00a0(4\u2013175 months). The mean age at presentation was 41 years\u00a0(19\u201374 years). Serous retinal detachment (202 eyes) and optic disc hyperaemia (89 eyes) were observed at presentation. Of\u00a0the patients tested, 45\/48 (93.8%) were human\u00a0leucocyte antigen-DR4 positive and 63\/77 (81.8%) had cerebrospinal fluid pleocytosis. Initial corticosteroid treatment consisted of pulse intravenous therapy in all patients. Sunset glow fundus was observed in 49.5% of eyes, and anterior and\/or posterior segment recurrence of inflammation was observed in 25 patients (22.5%). Treatment was transitioned to cyclosporine in 17 patients (15.3%) for steroid\u00a0sparing (6\u00a0patients) or recurrent inflammation (11 patients), with good subsequent control. Ocular complications were observed in 47 of 222 eyes (21.2%) (mostly cataract), and systemic complications were observed in 8.1% of patients (mostly hypertension and diabetes mellitus). Ninety-three percent of eyes (167 of 178 eyes) had a visual acuity of\u00a0\u22651.0 at 1\u2009year after presentation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An aggressive corticosteroid treatment strategy in a large number of patients with\u00a0new-onset acute VKH disease, with transitioning to cyclosporine in selected cases, resulted in excellent visual outcomes and low rates of recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjophthalmol-2017-311691","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T15:25:14Z","timestamp":1523978714000},"page":"274-278","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":67,"title":["Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids"],"prefix":"10.1136","volume":"103","author":[{"given":"Makiko","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Keino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayo","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle A","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"2024100707200663000_103.2.274.1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0002-9394(77)90142-8","article-title":"Vogt-Koyanagi-Harada syndrome","volume":"83","author":"Ohno","year":"1977","journal-title":"Am J Ophthalmol"},{"key":"2024100707200663000_103.2.274.2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.autrev.2016.04.001","article-title":"Vogt-Koyanagi-Harada syndrome: perspectives for immunogenetics, multimodal imaging, and therapeutic options","volume":"15","author":"Silpa-Archa","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2024100707200663000_103.2.274.3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2016.05.002","article-title":"Vogt-Koyanagi-Harada disease","volume":"62","author":"O'Keefe","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"2024100707200663000_103.2.274.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.08.030"},{"key":"2024100707200663000_103.2.274.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-002-0538-z"},{"key":"2024100707200663000_103.2.274.6","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1111\/aos.12127","article-title":"Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids","volume":"91","author":"Abu El-Asrar","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"2024100707200663000_103.2.274.7","first-page":"334","article-title":"Clinical studies of Vogt-Koyanagi-Harada\u2019s disease","volume":"32","author":"Ohno","year":"1988","journal-title":"Jpn J Ophthalmol"},{"key":"2024100707200663000_103.2.274.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)00937-0"},{"key":"2024100707200663000_103.2.274.9","doi-asserted-by":"publisher","DOI":"10.1159\/000310145"},{"key":"2024100707200663000_103.2.274.10","doi-asserted-by":"crossref","first-page":"674.e1","DOI":"10.1016\/j.ajo.2005.04.052","article-title":"Vogt-Koyanagi-Harada disease: clinical outcomes","volume":"140","author":"Bykhovskaya","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"2024100707200663000_103.2.274.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.07.044"},{"key":"2024100707200663000_103.2.274.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.02.049"},{"key":"2024100707200663000_103.2.274.13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0002-9394(02)01575-1","article-title":"Evaluation of pulse corticosteroid therapy assessed by optical coherence tomography","volume":"134","author":"Yamanaka","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"2024100707200663000_103.2.274.14","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318256205a"},{"key":"2024100707200663000_103.2.274.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)00925-4"},{"key":"2024100707200663000_103.2.274.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"2024100707200663000_103.2.274.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.12.009"},{"key":"2024100707200663000_103.2.274.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-014-2927-5"},{"key":"2024100707200663000_103.2.274.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.1.61"},{"key":"2024100707200663000_103.2.274.20","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2002.50003"},{"key":"2024100707200663000_103.2.274.21","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-007-9076-3"},{"key":"2024100707200663000_103.2.274.22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ajo.2016.03.045","article-title":"Long-term Outcomes of Limited Vogt-Koyanagi-Harada Syndrome","volume":"167","author":"Chew","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"2024100707200663000_103.2.274.23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/09273948.2015.1025984","article-title":"Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center","volume":"24","author":"Arevalo","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"2024100707200663000_103.2.274.24","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2008.89"},{"key":"2024100707200663000_103.2.274.25","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1111\/j.1755-3768.2010.02055.x","article-title":"Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt\u2013Koyanagi\u2013Harada disease","volume":"89","author":"Errera","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"2024100707200663000_103.2.274.26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09273940500536766","article-title":"Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy","volume":"14","author":"Paredes","year":"2006","journal-title":"Ocul Immunol Inflamm"},{"key":"2024100707200663000_103.2.274.27","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1111\/aos.12648","article-title":"Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease","volume":"93","author":"Urzua","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"2024100707200663000_103.2.274.28","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-007-9060-y"},{"key":"2024100707200663000_103.2.274.29","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181eef053"},{"key":"2024100707200663000_103.2.274.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-011-1910-7"},{"key":"2024100707200663000_103.2.274.31","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-308091"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-311691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T10:21:45Z","timestamp":1728296505000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-311691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,1,22]]},"published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1136\/bjophthalmol-2017-311691"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311691","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]}}}